Can a common diabetes drug reshape PCOS metabolism?

NCT ID NCT07759674

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This trial follows women with polycystic ovary syndrome (PCOS) who take metformin, a standard diabetes medication, for six months. Researchers track changes in insulin resistance, iron levels, erythropoietin, cholesterol, and blood counts at three and six months. The goal is to see whether routine metformin therapy improves these metabolic and blood-related markers in women with PCOS.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Metformin hydrochloride tablets, 500 mg taken twice daily for six months
What this could lead to
If successful, this could clarify how metformin improves metabolic and iron-related health in women with PCOS, potentially guiding better management of the condition.
What could go wrong
This is a small, single-center study with 25 participants, so results may not apply broadly. Metformin can cause gastrointestinal side effects, and the trial does not compare against a placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INSULIN RESISTANCE SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Ministry of Health Primary Healthcare Centers

    Amman, 009627, Jordan

More trials for these conditions

Other studies related to the condition(s) this trial covers.